2nd GPCRs-Targeted Drug Discovery Summit Europe

Europe is experiencing a renaissance in GPCR-targeted drug discovery. The unprecedented commercial success of GLP-1 receptor agonists in obesity has reignited investment, innovation, and clinical exploration across the GPCR space. With major deals such as Eli Lilly’s $1.3 billion collaboration to advance small-molecule GPCR therapeutics using AI- and ML-powered platforms, momentum is building fast, making 2025 a pivotal year to be part of this rapidly evolving field.

Returning as the only meeting dedicated exclusively to GPCR drug discovery and development in Europe, the 2nd Annual GPCR-Targeted Drug Discovery Summit Europe brings together the brightest minds in biopharma to translate this momentum into actionable strategies.

From expanding pipelines in cardiometabolic disease, neuroscience, oncology, and inflammation, to tackling biased signalling and optimising pharmacological modulation, this summit delivers the breadth and depth you need to progress differentiated, best-in-class GPCR-targeting drugs.

Whether you’re looking to identify new targets, enhance your discovery toolkit, or forge critical collaborations, this is your opportunity to stay ahead of the curve as biopharma redefines the druggable paradigm with next-generation GPCR therapeutics.


URLs:
Website: https://go.evvnt.com/3246067-0?pid=2874
Brochure: https://go.evvnt.com/3246067-3?pid=2874

Category: Conferences | Science, Health and Medicine | Pharmaceuticals

Prices:
Conference + 2 Workshops (Drug Developer Pricing): GBP 3597.00,
Conference + 1 Workshop (Drug Developer Pricing): GBP 3098.00,
Conference Only (Drug Developer Pricing): GBP 2599.00,
Conference + 2 Workshops (Academic Pricing): GBP 2997.00,
Conference + 1 Workshop (Academic Pricing): GBP 2598.00,
Conference Only (Academic Pricing): GBP 2199.00,
Conference + 2 Workshops (Service Provider Pricing): GBP 4297.00,
Conference + 1 Workshop (Service Provider Pricing): GBP 3698.00,
Conference Only (Service Provider Pricing): GBP 3099.00

Speakers: Shuguang Yuan, Co-Founder, Alphamol Science, Juan-Carlos Mobarec, Head of Computational Structural Biology, AstraZeneca, Dietmar Weichert, Principal Scientist, Boehringer Ingelheim, Christel Menet, Chief Scientific Officer, Confo Therapeutics, Stephan Schann, Chief Scientific Officer, Domain Therapeutics, Lewis Vidler, Senior Director - Structure Based Drug Design, Eli Lilly, Alejandra Tomas, Head of Section of Cell Biology and Functional Genomics, Imperial College London, Paul Groot-Kormelink, Associate Director in Discovery Sciences - Biomedical Research, Novartis, Laia Malet Sanz, Director - Medicinal Chemistry, OMass Therapeutics, Aurore Morello, Head of Research, Director of R and D Program, OSE Immunotherapeutics, Irina Tikhonova, Molecular Modelling Reader, Queen's University Belfast, Arne Christian, Rufer Expert Scientist, Roche, Robin Loving, Chief Scientific Officer, Salipro Biotech, Alexey Rak, Head of Bio Structure and Biophysics, Sanofi, Manel Kraiem, Chief Development Officer, Skymab Biotherapeutics, Chris de Graaf, Vice President - Head of Computational Drug Discovery and Data Science, Structure Therapeutics, Graeme Milligan, Professor of Biochemistry, University of Glasgow